Flucelvax (influenza vaccine (surface antigen, inactivated, prepared in cell cultures))
- Region
- 🇪🇺 EU
- Active substance
- influenza vaccine (surface antigen, inactivated, prepared in cell cultures)
- Company
- Seqirus Netherlands B.V.
- Status
- Authorised
- Therapeutic area
- Influenza, Human
- CHMP opinion
- Thu 17 Oct 2024
- EU approval
- Fri 15 Nov 2024
- Application
- EMEA/H/C/006532
- ATC
- J07BB02
- Official record
- www.ema.europa.eu
Indication
Prophylaxis of influenza in adults and children from 6 months of age. Flucelvax should be used in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Aujemflu Authorised · Seqirus Netherlands B.V.
- 🇪🇺 Fluad Authorised · Seqirus Netherlands B.V.
- 🇪🇺 Flucelvax Tetra Withdrawn · Seqirus Netherlands B.V.
- 🇪🇺 Fluad Tetra Withdrawn · Seqirus Netherlands B.V.
- 🇪🇺 Optaflu Expired · Seqirus GmbH
Follow Flucelvax
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.